Quantcast
Last updated on April 17, 2014 at 12:46 EDT

Latest Lupus Stories

2009-01-12 06:23:00

- Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus and ABthrax(R) for inhalation anthrax all progressing rapidly toward commercialization - - GSK Phase 3 trial of darapladib underway in chronic coronary heart disease - - HGS provides 2009 financial guidance; expects less than $25 million net cash burn - ROCKVILLE, Md., Jan. 12 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) will announce its priority goals for 2009 and report on the Company's progress toward...

2009-01-09 11:50:00

ANN ARBOR, Mich., Jan. 9 /PRNewswire/ -- A study published today in The Journal of Occupational and Environmental Medicine (http://tinyurl.com/9x2ebc) found that the mean annual price tag for lupus - including medical expenditures, absence from the job, and short-term disability costs - was nearly $20,000 per patient. The mean cost climbed to more than $60,000 per patient when lupus was accompanied by the kidney disease nephritis, as it often is. That's more than the average annual cost...

2009-01-06 15:30:00

NOVATO, Calif. and SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that they have entered into an agreement to develop and commercialize Riquent(R), La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Following a successful Phase 3 trial, the parties will share equally in all...

2008-12-23 14:44:24

Implications for new tests and more personalized treatments for autoimmune diseases More drafts usually mean a better product and so it also seems to go with the human immune system. As B cells develop, genes rearrange to allow their antibodies to recognize different foreign invaders or pathogens. But sometimes antibodies are created that recognize and attack the body's own cells. These self-reactive antibodies, like early drafts of a manuscript, must be edited into safer versions. This...

2008-10-27 15:00:09

SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- UCB (Euronext Brussels: UCB) announced data from two randomized controlled trials showing that treatment with epratuzumab a humanized anti-CD22 antibody, resulted in clinically meaningful reduced disease activity, improved health-related quality of life (HRQoL) measurements and reduced reliance on corticosteroids compared to placebo treatment in patients with active moderate and severe systemic lupus erythematosus (SLE). These findings were...

2008-10-15 18:59:39

Betty Diamond, M.D., Head of the Autoimmune Disease Center at The Feinstein Institute for Medical Research, and Professor of Medicine at the Albert Einstein College of Medicine, is the 2008 recipient of the prestigious Evelyn V. Hess Research Award, given annually by the Lupus Foundation of America, Inc. (LFA). The recipient is selected through a peer review process, and recognizes a lifetime of achievement in lupus research. Dr. Diamond has dedicated her professional career to patients...

2008-10-03 12:00:26

Because 90 percent of the estimated 1.5 million Americans living with the autoimmune disease lupus are female, fertility, pregnancy and reproductive health are important issues of concern. Women with lupus no longer are told not to have children. However, they are advised to take steps to plan before conception so physicians can monitor these high-risk pregnancies at every step. The Lupus Foundation of America will conduct a live chat through its website on the topic of "Reproductive...

2008-08-27 09:00:23

ROCKVILLE, Md., Aug. 27 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced it has completed enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials of LymphoStat-B(R) (belimumab) in patients with active systemic lupus erythematosus (SLE). Belimumab is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in August 2006. (Logo:...

2008-08-26 03:00:17

By Cooper, R G Magwere, T Chloroquine (CHQ) is a cheap, relatively well tolerated drug initially developed for the treatment of malaria in the 1930s. CHQ has, however, since accrued a plethora of uses in the treatment and amelioration of several other diseases and conditions because of its lysosomotropic properties. It also has characteristic physiological and systemic effects. This review gives an overview of the history and pharmacology of CHQ, and progresses to consider some of the...

2008-08-15 09:00:21

Medarex has announced that its partner MedImmune has initiated a Phase IIa multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus. MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System. Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount. The Phase IIa clinical trial is designed to evaluate the safety and tolerability of multiple subcutaneous dose...


Latest Lupus Reference Libraries

10_727908da8421f900a92d7a25ed6718ea2
2004-10-19 04:45:44

Lupus (the wolf) Constellation -- Lupus belongs to the constellations of the Southern Hemisphere roughly between DECL=-30 degrees and DECL=-55 degrees and RA=14h 20m and RA=16h 15m, respectively. It is located between Centaurus on the western and Scorpius and Norma on the eastern boundary. In the north Lupus borders on Libra, to the south it tops Circinus. As a part of the Milky Way stretches through Lupus it is an interesting part of the sky for simple stargazing with binoculars....

More Articles (1 articles) »